Kodiak Sciences Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
KOD$107.10+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Accrued and Other Current Liabilities
- Accrued and Other Current Liabilities
Accrued and other current liabilities consist of the following (in thousands):
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Accrued manufacturing and research & development costs | $16,216 | $6,238 |
| Accrued salaries and benefits | 4,961 | 7,770 |
| Accrued clinical trial and related costs | 6,401 | 4,494 |
| Accrued legal fees and professional fees | 537 | 824 |
| Accrued other liabilities | 2,205 | 1,281 |
| Total accrued and other current liabilities | $30,320 | $20,607 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.